Azathioprine and Allopurinol: How Low-Dose Combination Therapy Prevents Toxic Metabolite Buildup

LDAA therapy combines low-dose azathioprine with allopurinol to redirect toxic metabolite production toward therapeutic effects. It’s a proven solution for patients with high liver enzymes or poor response to standard thiopurine therapy, but requires strict monitoring to avoid bone marrow suppression.

Read More